
    
      The primary objective of this study is to evaluate the safety and efficacy of Besivanceâ„¢ as
      an antibiotic treatment for congenital nasolacrimal duct obstruction with infection in
      children. The primary outcome measure is the change from baseline on the physician rated
      scale of Nasolacrimal Duct Obstruction (NLDO)with infection to follow-up visit #2 (Week 8) or
      at the time of treatment failure, if earlier.
    
  